Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 12,286

Document Document Title
WO/2017/198775A1
The present invention relates to chiral phosphoramidites represented by formula (Ia) or formula (Ib) as novel monomers for the synthesis of stereodefined phosphorothioate MOE oligonucleotides. Furthermore, the present invention relates t...  
WO/2017/181193A3
The present disclosure provides compositions and methods for treating and/preventing diseases and conditions associated with premature termination mutations. The methods disclosed herein comprise the step of administering to the subject ...  
WO/2017/199028A1
A method of preparing an active agent or a salt thereof from a prodrug first compound (1) comprising a propargyl group connected to an oxygen that is directly or indirectly connected to the active agent is provided, wherein the bond betw...  
WO/2017/194498A1
The present invention relates to the field of stereodefined phosphorothioate oligonucleotides and to stereodefining nucleoside monomers and methods of synthesis of stereodefined oligonucleotides. Herein are disclosed solvent compositions...  
WO/2017/196697A1
This invention relates to novel implant drug delivery systems for long-acting delivery of antiviral drugs. These compositions are useful for the treatment or prevention of human immunodeficiency virus (HIV) infection.  
WO/2017/190715A1
The invention relates to a preparation method of an amorphous form of sofosbuvir of formula I, (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-l(2 H)-yl)-4- fluoro-3-hydroxy-4-memyltetrahydrofuran-2-yl)methoxy)-(ph...  
WO/2017/189978A1
This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or t...  
WO/2017/185549A1
Provided is a method for preparing nicotinamide mononucleotide. Raw materials nicotinamide, ATP, and ribose react under the catalytic effects of nicotinamide phosphoribosyltransferase, phosphoribose pyrophosphokinase, and ribokinase so a...  
WO/2017/184885A1
Compositions are provided including nicotinic acid riboside ("NAR"), and derivatives thereof including l -(2',3 ',5'-triacetyl-beta-D-ribofuranosyl)-nicotinic acid ("NAR triacetate" or "NARTA"); or derivatives of a reduced form of nicoti...  
WO/2017/183217A1
[Problem] To provide, as a substitute for a clinically used injected drug (5-azacytidine or 2'-deoxy-5-azacytidine), a 5-azacytidine or 2'-deoxy-5-azacytidine prodrug having high stability against the metabolic enzyme cytidine deaminase,...  
WO/2017/183215A1
[Problem] To provide, as a substitute for a clinically used injected drug (5-azacytidine or 2'-deoxy-5-azacytidine), a 5-azacytidine or 2'-deoxy-5-azacytidine prodrug having high stability against the metabolic enzyme cytidine deaminase,...  
WO/2017/184668A1
Provided are methods for treating Flaviviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I:, wherein the 1' position of the nucleoside sugar is substituted. The compounds, compositi...  
WO/2017/174322A1
The present invention relates to the field of powders, particularly food powders, and to the avoidance of caking in such powders by using compositions comprising dehydrated or partially dehydrated disodium inosine monophosphate salts.  
WO/2017/176677A1
This invention provides nucleotide analogues each of which comprises a tag comprising one or more Forster resonance energy transfer (FRET) acceptor fluorophores, a nucleotide polymerase having one or more FRET donor fluorophores, and met...  
WO/2017/170348A1
Provided are methods, uses, and compositions for treating acute myeloid leukemia which includes therapeutically effective combinations of 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin -1-yl]phenyl}amino)-5-(tetrahydro-2H-p...  
WO/2017/163186A1
The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these...  
WO/2017/162169A1
The present invention relates to a uridine phosphoramide prodrug, the preparation method therefor, and the medicinal uses thereof. The prodrug of the present invention is a chemical compound as shown in formula I, an optical isomer there...  
WO/2017/162536A1
Prodrugs of vortioxetine are provided  
WO/2017/160855A1
The present invention discloses a bone-targeting therapeutic conjugate comprising a formula of TG-M-D (I) or M-D-TG (II) and methods of making and using the same. The present invention also discloses a composition comprising the conjugat...  
WO/2017/157672A1
The present invention relates to the field of stereodefined phosphorothioate oligonucleotidess and to nucleoside monomers and methods of synthesis thereof. Herein are disclosed acyl protected L-LNA-G monomers which have improved solubili...  
WO/2017/160672A1
Modified Tryptamine, Tryptamine-2'-deoxy-uridine (TrpdU) and TrpdU-phosphoramidites for oligonucleotide synthesis are provided, as well as improved methods of their synthesis and oligonucleotides comprising at least one modified TrpdU nu...  
WO/2017/158624A1
The present disclosure provides novel crystalline sofosbuvir form- M3 and a process for the preparation of sofosbuvir form-M3. The crystalline sofosbuvir form-M3 disclosed herein may be useful in the formulation of pharmaceutical dosage ...  
WO/2017/161349A1
Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.  
WO/2017/157356A1
Compounds of general formulae6 and 13 where X is -NH-C(NH2)=N+H2 or -N+H3, Y is a linear oligomer consisting of arginine units terminated with an aminodimethylenamide unit (-Arg)n-NH-(CH2)2-NH2, where n = 6-10, or arginine-aminocaproic u...  
WO/2017/160741A1
The present disclosure, among other things, provides technologies for preparing and purifying phosphoramidites for oligonucleotide synthesis.  
WO/2017/160793A1
Provided herein a re composition and process for using an electrochemica l device for the reduction of the oxidized state of phosphorylated or non-phosphorylated nicotinamide adenine dinucleotide to the reduced state in which unwanted pr...  
WO/2017/153936A1
This invention provides messenger RNA (mRNA) molecules comprising comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), ...  
WO/2017/155923A1
This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or t...  
WO/2017/153186A1
The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invent...  
WO/2017/154938A1
[Problem] The purpose of the present invention is to provide a method for uniformly and efficiently producing a sugar having a sulfate group and/or phosphate group in the molecule or a compound containing the sugar. [Solution] The presen...  
WO/2017/156380A1
This disclosure relates to certain N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of a Zika virus infection.  
WO/2017/143453A1
This disclosure provides methods and strategies for inhibiting the growth of TP53 wild-type cancer cells, comprising contacting the cell with 2',2'-difluoro-5-aza-2'- deoxycytidine or a 2',2'-difluoro-5-aza-2'-deoxycytidine prodrug. Also...  
WO/2017/145151A1
Disclosed herein is a process for preparing nicotinamide riboside (NR) from an NR precursor and a phosphate-binding agent in a solvent. The reaction-derived mixture comprising NR may be further used without further processing in a variet...  
WO/2017/144423A1
The present invention relates to a process for the synthesis of Sofosbuvir of formula (I) comprising the selective mono-deacetylation reaction of a compound of formula (V) to obtain a compound of formula (IV).  
WO/2017/143113A1
The present invention is directed to methods for the use of 5 '-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing adenovirus- related diseases or conditions, eye disorders, cancer, or di...  
WO/2017/142984A1
The application provides methods for treatment or prophylaxis of Zika Virus mediated diseases with compounds of Formula I, wherein the variables R1, R2, R3, R4, R5, and Base are defined as described hereinabove.  
WO/2017/142913A1
A method for making a polynucleotide is provided that includes (a) delivering one or more reaction reagents including an error prone or template independent DNA polymerase, cations and a selected nucleotide to a reaction site including a...  
WO/2017/142054A1
Provided is an artificial nucleoside or an artificial nucleotide which can constitute an artificial oligonucleotide having excellent nuclease resistance. An artificial nucleoside or an artificial nucleotide, which is a compound represent...  
WO/2017/137374A1
The present invention concerns methods and approaches for modifying guanosine tetraphosphate (ppGpp) homeostasis in photosynthetic eukaryotes, in particular plants or algae, in order to modulate senescence for the remobilisation of nitro...  
WO/2017/124315A1
A method for enzymatic preparation of fludarabine phosphate, comprising reaction of fludarabine with a high-energy phosphate compound under the action of deoxyribonucleic acid kinase. According to said method, acetate kinase and acetyl p...  
WO/2017/127357A1
A DNA aptamer is provided that binds to a cholecystokinin B receptor (CCBKR), allowing for delivery of therapeutic agents or imaging agents to cells having the CCBKR. Compositions and methods of use are provided where the aptamer binds t...  
WO/2016/205738A3
The present invention provides a compound having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, for the controlled delivery and release of Agent.  
WO/2017/118355A1
Provided in the present application are a nucleotide derivative of a deuterated HCV (Hepatitis C Virus) NS5b inhibitor, or a pharmaceutically acceptable salt, stereoisomer, tauromer inhibitor thereof, and a use thereof in the preparation...  
WO/2017/120508A1
Compounds that modulate the conversion of AMP to adenosine by 5'- nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions ...  
WO/2017/115301A1
The present disclosure provides methods for the treatment of breast cancer, including triple negative breast cancer. Said methods comprise the administration of (a) a cationic liposomal formulation comprising a taxane, (b) a non-liposoma...  
WO/2017/109485A1
This invention relates to a crystalline form of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-(S)-phosphate.  
WO/2017/110317A1
A nicotinamide mononucleotide derivative represented by general formula (1) or a salt thereof. (In the formula, R1 and R2 each independently represent a hydrogen atom or an acyl group having 3-30 carbon atoms. A hydrocarbon group bonded ...  
WO/2017/104836A1
The present invention provides an oligonucleotide production method that includes: (1) a step in which a reaction liquid comprising a phosphite triester body (c) is obtained by condensing, in a nonpolar solvent, a nucleoside, nucleotide,...  
WO/2017/101785A1
Disclosed in the present invention are a prodrug comprising a nucleoside analog structure as shown in formula I, a tautomer thereof, a stereisomer thereof, a stereisomer mixture thereof or a pharmaceutically acceptable solvate thereof. A...  
WO/2017/101890A1
The present invention relates to a spiroketal derivative having formula (I), a preparation method therefor and an application. R1, R2, R3, R4, X and the A ring are defined in the description. The derivative is an intestine or kidney gluc...  

Matches 251 - 300 out of 12,286